ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Revenue of ALX Oncology Holdings Inc. (ALXO)
Revenue in 2023 (TTM): $
According to ALX Oncology Holdings Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of ALX Oncology Holdings Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-836,000 | $-158,404,000 | $-160,805,000 | $-160,805,000 |
| 2022 | $ | $-1,466,000 | $-121,952,000 | $-123,418,000 | $-123,482,000 |
| 2021 | $ | $-736,000 | $-83,471,000 | $-83,484,000 | $-83,463,000 |
| 2020 | $1.18 M | $107 K | $-43,461,000 | $-45,499,000 | $-45,740,000 |
| 2019 | $4.8 M | $436 K | $-18,759,000 | $-19,209,000 | $-19,243,000 |
| 2018 | $2.07 M | $187 K | $-13,255,000 | $-13,686,000 | $-13,731,000 |